Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Moodys
McKesson
Merck
Boehringer Ingelheim

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,067,451

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,067,451 protect, and when does it expire?

Patent 8,067,451 protects DUEXIS and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.

Summary for Patent: 8,067,451
Title:Methods and medicaments for administration of ibuprofen
Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.
Inventor(s): Tidmarsh; George (Portola Valley, CA), Golombik; Barry L. (Incline Village, NV), Sharma; Puneet (Gaithersburg, MD)
Assignee: Horizon Pharma USA, Inc. (Northbrook, IL)
Application Number:11/779,204
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,067,451
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Process; Use;

Drugs Protected by US Patent 8,067,451

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes   Start Trial   Start Trial Y RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,067,451

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 539747   Start Trial
Australia 2006269894   Start Trial
Australia 2007275360   Start Trial
Brazil PI0714937   Start Trial
Canada 2615496   Start Trial
Canada 2657928   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
AstraZeneca
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.